Gilead Sciences (GILD) Competitors $106.54 +2.33 (+2.24%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock GILD vs. AMGN, VRTX, REGN, ALNY, BIIB, UTHR, BMRN, INCY, EXEL, and NBIXShould you be buying Gilead Sciences stock or one of its competitors? The main competitors of Gilead Sciences include Amgen (AMGN), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Exelixis (EXEL), and Neurocrine Biosciences (NBIX). These companies are all part of the "biotechnology" industry. Gilead Sciences vs. Amgen Vertex Pharmaceuticals Regeneron Pharmaceuticals Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Incyte Exelixis Neurocrine Biosciences Gilead Sciences (NASDAQ:GILD) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership. Do institutionals and insiders believe in GILD or AMGN? 83.7% of Gilead Sciences shares are held by institutional investors. Comparatively, 76.5% of Amgen shares are held by institutional investors. 0.3% of Gilead Sciences shares are held by company insiders. Comparatively, 0.7% of Amgen shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth. Which has more volatility and risk, GILD or AMGN? Gilead Sciences has a beta of 0.32, suggesting that its share price is 68% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Which has better valuation & earnings, GILD or AMGN? Amgen has higher revenue and earnings than Gilead Sciences. Gilead Sciences is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGilead Sciences$28.74B4.57$480M$4.7522.21Amgen$33.42B4.65$4.09B$7.5538.29 Does the media refer more to GILD or AMGN? In the previous week, Gilead Sciences had 25 more articles in the media than Amgen. MarketBeat recorded 71 mentions for Gilead Sciences and 46 mentions for Amgen. Amgen's average media sentiment score of 1.06 beat Gilead Sciences' score of 0.61 indicating that Amgen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gilead Sciences 21 Very Positive mention(s) 5 Positive mention(s) 22 Neutral mention(s) 8 Negative mention(s) 2 Very Negative mention(s) Positive Amgen 27 Very Positive mention(s) 3 Positive mention(s) 12 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Does the MarketBeat Community prefer GILD or AMGN? Gilead Sciences received 931 more outperform votes than Amgen when rated by MarketBeat users. Likewise, 76.86% of users gave Gilead Sciences an outperform vote while only 71.81% of users gave Amgen an outperform vote. CompanyUnderperformOutperformGilead SciencesOutperform Votes248576.86% Underperform Votes74823.14% AmgenOutperform Votes155471.81% Underperform Votes61028.19% Is GILD or AMGN more profitable? Amgen has a net margin of 12.24% compared to Gilead Sciences' net margin of 1.67%. Amgen's return on equity of 176.32% beat Gilead Sciences' return on equity.Company Net Margins Return on Equity Return on Assets Gilead Sciences1.67% 31.63% 10.38% Amgen 12.24%176.32%11.71% Is GILD or AMGN a better dividend stock? Gilead Sciences pays an annual dividend of $3.16 per share and has a dividend yield of 3.0%. Amgen pays an annual dividend of $9.52 per share and has a dividend yield of 3.3%. Gilead Sciences pays out 66.5% of its earnings in the form of a dividend. Amgen pays out 126.1% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Amgen has raised its dividend for 14 consecutive years. Amgen is clearly the better dividend stock, given its higher yield and longer track record of dividend growth. Do analysts prefer GILD or AMGN? Gilead Sciences presently has a consensus target price of $109.43, suggesting a potential upside of 3.75%. Amgen has a consensus target price of $310.57, suggesting a potential upside of 7.42%. Given Amgen's higher possible upside, analysts clearly believe Amgen is more favorable than Gilead Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gilead Sciences 0 Sell rating(s) 9 Hold rating(s) 15 Buy rating(s) 3 Strong Buy rating(s) 2.78Amgen 2 Sell rating(s) 10 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.43 SummaryAmgen beats Gilead Sciences on 13 of the 22 factors compared between the two stocks. Get Gilead Sciences News Delivered to You Automatically Sign up to receive the latest news and ratings for GILD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GILD vs. The Competition Export to ExcelMetricGilead SciencesBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$131.34B$2.98B$5.55B$7.75BDividend Yield3.06%1.89%5.11%4.22%P/E Ratio285.0830.3322.4218.43Price / Sales4.57496.43393.41102.88Price / Cash12.66168.6838.1834.62Price / Book6.833.166.724.23Net Income$480M-$72.35M$3.22B$248.23M7 Day Performance-0.89%2.44%2.66%2.79%1 Month Performance-5.64%-0.90%-0.51%1.94%1 Year Performance61.78%-21.69%17.84%5.20% Gilead Sciences Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GILDGilead Sciences4.6998 of 5 stars$106.54+2.2%$109.43+2.7%+58.0%$132.66B$28.74B287.9517,000Earnings ReportDividend AnnouncementAnalyst RevisionAMGNAmgen4.0678 of 5 stars$280.90+0.0%$310.57+10.6%+4.4%$151.04B$33.42B37.2125,200Upcoming EarningsPositive NewsVRTXVertex Pharmaceuticals3.9294 of 5 stars$493.720.0%$514.91+4.3%+27.1%$126.63B$11.02B-224.154,800Upcoming EarningsAnalyst RevisionPositive NewsREGNRegeneron Pharmaceuticals4.828 of 5 stars$604.30+0.3%$945.32+56.4%-36.3%$66.02B$14.20B15.7811,900Earnings ReportDividend AnnouncementAnalyst ForecastALNYAlnylam Pharmaceuticals4.307 of 5 stars$253.33+0.7%$315.58+24.6%+74.5%$32.90B$2.25B-116.532,000Upcoming EarningsAnalyst DowngradeNews CoveragePositive NewsBIIBBiogen4.6879 of 5 stars$118.73-0.1%$203.07+71.0%-44.2%$17.38B$9.68B10.618,720Upcoming EarningsAnalyst DowngradeAnalyst RevisionUTHRUnited Therapeutics4.9052 of 5 stars$295.32+1.4%$390.17+32.1%+26.2%$13.23B$2.88B12.94980Earnings ReportAnalyst RevisionNews CoveragePositive NewsGap UpBMRNBioMarin Pharmaceutical4.9207 of 5 stars$62.61-1.1%$93.14+48.8%-23.0%$11.93B$2.85B28.423,080Upcoming EarningsPositive NewsINCYIncyte4.714 of 5 stars$59.03-0.2%$74.69+26.5%+15.0%$11.42B$4.24B218.492,320Earnings ReportAnalyst ForecastNews CoverageEXELExelixis4.0767 of 5 stars$38.18+2.0%$37.59-1.5%+62.5%$10.51B$2.17B21.541,220Short Interest ↑Analyst RevisionPositive NewsNBIXNeurocrine Biosciences4.862 of 5 stars$105.37-1.3%$160.90+52.7%-22.8%$10.42B$2.36B32.001,200Upcoming EarningsAnalyst ForecastAnalyst Revision Related Companies and Tools Related Companies AMGN Competitors VRTX Competitors REGN Competitors ALNY Competitors BIIB Competitors UTHR Competitors BMRN Competitors INCY Competitors EXEL Competitors NBIX Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GILD) was last updated on 4/30/2025 by MarketBeat.com Staff From Our Partners"I'm risking my reputation on this"I've discovered something so significant about the 2025 crypto market that I had to put everything else aside ...Crypto 101 Media | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big ch...Paradigm Press | SponsoredSecret financial plot unfolding in Washington DC… [DEVELOPING]What stocks are next up to soar in 2025? I believe I’ve found the answer - and it might surprise you. Yo...Timothy Sykes | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | SponsoredIf you missed your chance with Tesla...Elon Musk is moments from launching a revolutionary technology some Silicon Valley insiders are calling "The F...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Gilead Sciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Gilead Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy GILD Stock Free GILD Stock Alerts